

IN THE SPECIFICATION

1. Delete the paragraph on page 18, lines 23-25, and replace it with:

Oil-emulsion compositions suitable for use as adjuvants in the invention include squalene-water emulsions, such as MF59® MF59 (5% Squalene, 0.5% TWEEN® 80 Tween 80, and 0.5% SPAN® 85 Span 85, formulated into submicron particles using a microfluidizer). See ref. 45.

2. Delete the paragraph on page 21, lines 32-33, and replace it with:

Examples of imidazoquinolone compounds suitable for use adjuvants in the invention include Imiquimod Imiquimed and its homologues, described further in Ref. 80 and 81.

3. Delete the paragraphs on page 22, lines 6-12, and replace them with:

(5) SAF, containing 10% squalene Squalane, 0.4% TWEEN® 80 Tween 80, 5% pluronic-block polymer L121, and thr-MDP, either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion.

(6) RIBI™ Ribi™ adjuvant system (RAS), (Ribi Immunochem) containing 2% Squalene, 0.2% TWEEN® 80 Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL+CWS (DETOX™ Detox™), and

4. Delete the paragraph on page 22, lines 15-16, and replace it with:

Aluminium salts and MF59® MF59 are preferred adjuvants for parenteral immunisation. Mutant bacterial toxins are preferred mucosal adjuvants.

5. Delete the paragraph on page 23, line 5, and replace it with:

– rabies antigen(s) [e.g. 126] such as lyophilised inactivated virus [e.g. 127, RABAVERT™ RabAvert™].